Harbige, GB
David Harbige, Norfolk GB
Patent application number | Description | Published |
---|---|---|
20130117573 | METHOD FOR VERIFYING A PASSWORD - A method for verifying a password in a computing device, wherein the computing device comprises: a user input interface; a trusted hardware module having a trusted application stored therein, the trusted hardware module arranged to provide the trusted application with access to at least said user input interface; and a secure verification application for verifying the password; the method comprising: the trusted application receiving a request to obtain a user password; the trusted hardware module providing the trusted application with access to the user input interface; the user entering a password using the user input interface; the trusted application encoding the entered password; passing the encoded password to the secure transaction application; and decoding the password. | 05-09-2013 |
Laurence Harbige, Chatham Kent GB
Patent application number | Description | Published |
---|---|---|
20120135992 | CYCLIC TRIAZO SODIUM CHANNEL BLOCKERS - The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The compounds are of formula (I): in which z is a single bond or an optionally substituted linking group, R1 is a halo-alkyl group; and A is an optionally substituted aromatic heterocyclic or carbocyclic ring system; or a salt thereof. | 05-31-2012 |
20120135993 | CYCLIC TRIAZO SODIUM CHANNEL BLOCKERS - The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The triazine compounds are of formula (I) wherein: R1 is hydrogen or a substituent group; R2 is amino or a substituent group; N* is amino when R1 is hydrogen or ═NH when R1 is a substituent group; R3 and R4 are both carbocyclic, heterocyclic or alkyl groups and may be same or different; and R5 is hydrogen, alkyl or a cyclic aryl group, with the proviso that: when R3 and R4 are both alkyl they are linked to form a cycloalkyl group, and R5 is a cyclic aromatic group; and when R3 and R4 are both carbocyclic or heterocyclic groups, R5 is hydrogen or an alkyl group; or a salt thereof. | 05-31-2012 |
20140243343 | CYCLIC TRIAZO SODIUM CHANNEL BLOCKERS - The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The compounds are of formula I: | 08-28-2014 |
Laurence Harbige, Chatham GB
Patent application number | Description | Published |
---|---|---|
20140155403 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS - A method of treating a disorder. The method includes administering to a subject in need thereof a compound of formula (I): | 06-05-2014 |
Laurence Harbige, Kent GB
Patent application number | Description | Published |
---|---|---|
20090291954 | Medical Use of Triazine Derivatives - Compounds of formula (I) especially where R | 11-26-2009 |
20110009413 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS - Compounds of general structure in which X and Y are each N or C with at least one of X and Y being N; Z is a single bond or an optionally substituted linking group R1 is hydrogen or a substituent group; R2 is amino or a substituent group; N* is amino when RI is hydrogen or ═NH when R1 is a substituent group; or N* is a group NRaRb where Ra and Rb are independently H or an alkyl group; or N* is an optionally substituted piperazinyl ring; and A is an optionally substituted heterocyclic or carbocyclic ring system which may be linked to the triazo/diazo ring through R2 to form a fused multicyclic ring; are indicated as suitable for treatment of disorders in mammals that are susceptible to sodium channel blockers and antifolates, and particularly disorders such epilepsy, multiple sclerosis, glaucoma and uevitis, cerebral traumas and cerebral ischaemias, stroke, head injury, spinal cord injury, surgical trauma, neurodegenerative disorders, motorneurone disease, Alzheimer's disease, Parkinson's disease, chronic inflammatory pain, neuropathic pain, migraine, bipolar disorder, mood, anxiety and cognitive disorders, schizophrenia and trigeminal autonomic cephalalgias; for treatment of mammalian cancers; and for treatment of malaria. | 01-13-2011 |
20130005732 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES - Compounds of formula (I): | 01-03-2013 |
Laurence S. Harbige, London GB
Patent application number | Description | Published |
---|---|---|
20090036410 | Structured Phospholipids - A method of treating a patient in need of therapy for a disease in which cyokines have become dysregulated, or are otherwise capable of modulation to provide therapeutic benefit, is provided comprising administering to that patient a therapeutically effective dose of a phospholipid comprising a phosphatidyl group esterifed with one or more fatty acyl groups, characterised in that the phospholipid has at least one fatty acyl group at the sn-1 and/or sn-2 position of the phosphatidyl group, the fatty acyl group being selected from the group consisting of γ-linolenoyl, dihomo-γ-linolenoyl acid and arachidonoyl. | 02-05-2009 |
20100113810 | Treatment of neurodegenerative conditions - A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels. | 05-06-2010 |
20110184063 | Treatment of neurodegenerative conditions - A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a triglyceride oil containing both γ-linolenic acid and linoleic acid residues as triglyceride ester, the ratio of γ-linolenic acid to linoleic acid residues at the sn-2 position of the triglyceride being at least 0.8; the amount of γ-linolenic acid residues at the sn-2 position being at least 18%, wherein the oil is administered at a dose sufficient to maintain or elevate TGF-β1 levels in the patient at a therapeutic level. Preferably the method is that wherein the therapeutic level is such as to produce a TGF-β1/TNF-α ratio of at least 0.5 in blood of a patient, after 18 months of daily dosing. Preferred oils are Borage or Mucor oils having at least 35% of the sn-2 position fatty acid residues as γ-linolenic acid. | 07-28-2011 |
20120142775 | TREATMENT OF NEURODEGENERATIVE CONDITIONS - A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels. | 06-07-2012 |
Laurence S. Harbige, Kent GB
Patent application number | Description | Published |
---|---|---|
20090023807 | Treatment of Cytokine Dysregulation by Using Sn-2 Gamma-Linolenoyl, Gamma-Diho-Molinolenoyl or Arachidonoyl Patty Acid Glycerol Monoesters - A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a monoglyceride or metabolic precursor thereof of general formula (I), wherein R | 01-22-2009 |
20090137660 | Cytokine Modulators Using Cyclic Glycerides of Essential Polyunsaturated Fatty Acids - A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R | 05-28-2009 |
20100297196 | Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids - A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R | 11-25-2010 |
Lawrence S. Harbige, London GB
Patent application number | Description | Published |
---|---|---|
20100113595 | Treatment of neurodegenerative conditions - A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels. | 05-06-2010 |